A United States cost-benefit comparison of an apodized, diffractive, presbyopia-correcting, multifocal intraocular lens and a conventional monofocal lens
A United States cost-benefit comparison of an apodized, diffractive, presbyopia-correcting, multifocal intraocular lens and a conventional monofocal lens
复制标题
DOI：
10.1016/j.jcrs.2008.07.024
复制
发表时间：
2008-11-01
影响因子：
2.8
通讯作者：
Hileman, Kendra
中科院分区：
文献类型：
--
作者：
Maxwell, William A.;Waycaster, Curtis R.;Hileman, Kendra
目得：从患者的角度证明变迹衍射老视矫正多焦点人工透镜（MF-IOL）与传统单焦点人工透镜（CM-IOL）相比的价值。设置：开放标签，多地点美国临床试验。方法：使用白内障患者的支付意愿（WTP）作为经济效益的衡量标准进行成本效益分析。在比较MF-IOL和CM-IOL的临床试验中，从参与者中得出WTP。患者承担的费用来自标准参考来源。采用了14年的分析时间框架，并对成本和收益采用了3%的年贴现率。利息的结果是净收益（收益和成本之间的差额）。一个概率敏感性分析被用来确认的经济results.RESULTS的鲁棒性：四百九十五例患者提供的WTP估计眼镜的独立性（MF-IOL，n = 339; CM-IOL，n = 156）。80%的患者愿意每天支付至少5美元来独立使用眼镜。与双侧植入2枚MF-IOL相关的增量购置成本估计为4，000美元。MF-IOL组中80%的患者和CM-IOL组中8%的患者报告了术后眼镜独立性。MF-IOL组的净获益为11，670美元，CM-IOL组为155美元。概率敏感性分析证实了稳健性的经济outcomes.CONCLUSION：MF-IOL的净效益超过其收购成本和CM-IOL的净效益，证明了其价值，选择白内障患者愿意支付溢价眼镜独立。
PURPOSE: To demonstrate the value, from the patient's perspective, of an apodized, diffractive, presbyopia-correcting multifocal intraocular lens (MF-IOL) compared to a conventional monofocal intraocular lens (CM-IOL).SETTING: Open-label, multi-site U.S. clinical trial.METHODS: A cost-benefit analysis was conducted using cataract patients' willingness-to-pay (WTP) for spectacle independence as the measure of economic benefit. WTP was elicited from participants in a clinical trial comparing a MF-IOL and a CM-IOL. Costs borne by patients were obtained from standard reference sources. A 14-year analytical timeframe was used, and a 3% annual discount rate was applied to both costs and benefits. The outcome of interest was net benefit (difference between benefits and costs). A probabilistic sensitivity analysis was used to confirm the robustness of the economic results.RESULTS: Four hundred ninety-five patients provided WTP estimates for spectacle independence (MF-IOL, n = 339; CM-IOL, n = 156). Eighty percent of all patients were willing to pay at least $5 per day to be spectacle independent. The incremental acquisition cost associated with bilateral implantation of 2 MF-IOLs was estimated at $4,000. Eighty percent in the MF-IOL group and 8% in the CM-IOL group reported post-operative spectacle independence. The net benefit was $11,670 in the MF-IOL group and $155 in the CM-IOL group. The probabilistic sensitivity analysis confirmed the robustness of the economic outcomes.CONCLUSION: The net benefit of the MF-IOL exceeded its acquisition cost and the net benefit of the CM-IOL, demonstrating its value to select cataract patients willing to pay a premium for spectacle independence.